Video Shorts

Selecting the right patients for early initiation of hypomethylating agents (HMAs) in low-risk MDS involves identifying those with progressive cytopenias, poor prognostic mutations, or high-risk features despite low-risk classification.

Anticipate & manage adverse events to optimize treatment outcomes: Patients treated with hypomethylating agents are at increased risk of cytopenias & might need support with transfusions.

Immune cells known as tumor-infiltrating lymphocytes (TILs) are thought to be a promising, affordable biomarker with prognostic and predictive potential.

In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.

Average at diagnosis of prostate cancer is ~65 years & patients usually have multiple co- morbidities and may be on treatment with multiple prescribed medications.

There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.

Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.

Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.

Tissue-agnostic treatment based on shared genetic aberrations have provided a new direction in cancer treatment. Emerging clinical evidence indicates that many molecular aberrations can be common across tumor types with different site of origin.

Breast Cancer is heterogenous disease & ER+ve & Her2 Negative (Luminal) is most common subtype of Breast Cancer. For ER+ve & Her2 Negative patients endocrine therapy remains the most important systemic treatment option.